For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ DSIP
Illustration for DSIP

THE PEPSRADAR ENCYCLOPEDIA

DSIP

Experimental sleep regulation

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

DSIP · KEY FACTS

Content updated · how dates work

What is DSIP?

DSIP stands for delta sleep-inducing peptide. The name reflects its research history, while actual sleep outcomes require direct measurement.

Biological role or research focus

Experimental sleep regulation.

The name “sleep-inducing” is not proof of a meaningful improvement in chronic insomnia.

Role reference: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

Names you may encounter

emideltide · delta sleep inducing peptide

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Experimental sleep-related peptide
Main research area
Sleep physiology
Evidence featured
Small blinded human study
Source check
October 4, 2026

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

Quick answers

Is DSIP FDA approved?
No. No FDA-approved drug contains DSIP. Source ↗
Is DSIP safe?
DSIP (emideltide) is unapproved. Small, older human studies exist, but FDA judged its safety insufficiently characterized and noted headache, nausea, vertigo and low blood pressure reports. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
Is DSIP banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
Has the FDA taken action over DSIP?
Yes. Our records list 2 FDA actions naming it, most recently on July 1, 2026: FDA presented emideltide (DSIP) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
Chronic insomnia experiment (1992)Small blinded human study16 people with chronic insomnia.
DSIP · six-volunteer sleep experiment (1981)Small human crossover studySix healthy volunteers, four men and two women.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Small blinded human study · 1992

Chronic insomnia experiment

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Population / model
16 people with chronic insomnia.
Study design
Matched-pairs parallel groups; five laboratory nights including baseline, followed by three treatment nights.
Main finding
Some objective sleep measures changed modestly, but subjective sleep quality did not improve. The authors considered major short-term therapeutic benefit unlikely.
Limits & context
The small sample, short duration, and partly placebo-driven differences limit confidence. The name “delta sleep-inducing peptide” is not itself evidence of an insomnia treatment.

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

Small human crossover study · 1981

DSIP · six-volunteer sleep experiment

How does an early sleep signal compare with the later insomnia trial?

Population / model
Six healthy volunteers, four men and two women.
Study design
Double-blind crossover experiment with placebo, short-term sleep monitoring, and subsequent-night measurements.
Main finding
Median total sleep time increased 59% within a 130-minute observation interval. Shorter sleep onset and improved sleep efficiency were reported for the following night.
How to read it
The percentage describes a short observation window, not a sustained increase in nightly sleep or successful treatment of chronic insomnia.
Limits & context
Six healthy participants and brief monitoring cannot establish long-term efficacy or uncommon harms. Read alongside the later 16-person insomnia study, which found limited benefit. Absence of observed side effects is not proof of safety.

Source: DSIP · six-volunteer sleep experiment · 1981 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming DSIP as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Search additional PubMed records ↗

Risks & interactions

DSIP (emideltide) is unapproved. Small, older human studies exist, but FDA judged its safety insufficiently characterized and noted headache, nausea, vertigo and low blood pressure reports.

Human safety data: Very limited

Small intravenous studies in insomnia reported no significant adverse effects; studies in drug or alcohol withdrawal reported side effects that withdrawal itself may confound. FDA found no safety data for the subcutaneous route proposed for compounding.

Unassessed: little human safety data

Take extra care with: Heart or blood pressure problems

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • Progressive low blood pressure reported after a repeat infusion in withdrawal studies (FDA review)
  • FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products

Side effects reported in studies

  • headache
  • nausea
  • vertigo
  • sweating

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA briefing document: emideltide (DSIP) (Pharmacy Compounding Advisory Committee, 2026) ↗ · FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · DSIP in chronic insomnia: double-blind study (1992) ↗ · DSIP effects on human sleep behavior (1981) ↗

Safety evidence & remaining uncertainty

FDA identifies a safety-data gap. The small sleep study cannot characterize uncommon adverse effects or repeated long-term exposure.

Source: FDA · Peptide compounding safety concerns ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Emideltide (DSIP)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA presented emideltide (free base and acetate) to its Pharmacy Compounding Advisory Committee on July 24, 2026, proposing that it NOT be added to the 503A bulks list. source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

FDA actions

  • FDA presented emideltide (DSIP) to its Pharmacy Compounding Advisory Committee (July 24, 2026) for possible addition to the 503A bulks list; FDA's briefing document proposed NOT adding it. The committee's vote is advisory; no final FDA decision found. (2026-07) source
  • FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing DSIP among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

The selected insomnia experiment provides limited human evidence, with weak objective changes and no subjective sleep-quality benefit. It does not establish a routine treatment for chronic insomnia.

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Mechanism & research rationale

DSIP has been examined as a modulator of sleep. Its name does not specify a clinically established mechanism or guarantee an effect on restorative sleep.

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

Molecular structure

DSIP: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 68816 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • The name “sleep-inducing” is not proof of a meaningful improvement in chronic insomnia.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Does “sleep-inducing” mean proven insomnia treatment?

No. A compound name can outlast the hypothesis that produced it. The controlled findings matter more.

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

Were participants simply asked whether they slept better?

The study used objective sleep recordings as well as subjective measures, and the two did not show a consistent benefit.

Source: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

DSIP

Download illustration ↓Source record ↗
DSIP 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.